Nurami key facts
as of Oct 2026- Developer of biomaterials and nanofiber-based matrix designed to improve patient outcomes in various surgical procedures.
- Nurami is valued at approximately $61.4M as of Oct 2026 (last reported valuation).
- It has raised $43.7M; the latest was Later Stage VC ($30.0M) in Jun 2025.
- Notable investors include European Innovation Council, MedTech Innovator, Innovation Authority, Matter (Consulting Services (B2B)), Arieli Group — 16 tracked in total.
- Status: Privately Held (backing).
Nurami's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Nurami: the Monday email on marks, rounds and moves
Nurami funding rounds
No funding rounds for Nurami are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Nurami
16+Membership and data by Private Market View
Nurami valuation
Nurami's last reported valuation was $61.4 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Nurami investors
16 investors are on record for Nurami, including European Innovation Council, MedTech Innovator, Innovation Authority and Matter (Consulting Services (B2B)).
About Nurami
Developer of biomaterials and nanofiber-based matrix designed to improve patient outcomes in various surgical procedures. The company's matrices combine porous scaffold for tissue regeneration enhancement with a novel temperature-sensitive sealant to prevent the entry of pathogens and CSF leaks, enabling surgeons to answer the unmet needs of their patients.
- Sector
- Healthcare
- HQ
- Haifa, Israel
- Founded
- 2014
- Employees
- 28
- Website
- nurami-medical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.